Melatonin treatment in adolescents with delayed sleep phase syndrome

Clin Pediatr (Phila). 2006 Nov;45(9):809-18. doi: 10.1177/0009922806294218.

Abstract

This retrospective study describes the effects of long-term treatment with melatonin in 33 adolescents (age range, 10-18 years) with delayed sleep phase syndrome (DSPS). Patients were treated with oral melatonin, 3 to 5 mg/day for an average period of 6 months. During the treatment, sleep onset was advanced and sleep duration was longer. Treatment was also associated with a decrease in the proportion of patients reporting school difficulties. No adverse effects of melatonin were noted. This study indicates that long-term treatment with melatonin can be beneficial for adolescents with DSPS in terms of sleep-wake schedule and school performance.

MeSH terms

  • Administration, Oral
  • Adolescent
  • Age Factors
  • Analysis of Variance
  • Attention Deficit Disorder with Hyperactivity / complications
  • Attention Deficit Disorder with Hyperactivity / drug therapy
  • Case-Control Studies
  • Child
  • Circadian Rhythm / drug effects
  • Female
  • Follow-Up Studies
  • Humans
  • Israel
  • Male
  • Melatonin / administration & dosage
  • Melatonin / therapeutic use*
  • Psychomotor Performance / drug effects
  • Research Design
  • Retrospective Studies
  • Sleep / drug effects
  • Sleep Disorders, Circadian Rhythm / complications
  • Sleep Disorders, Circadian Rhythm / diagnosis
  • Sleep Disorders, Circadian Rhythm / drug therapy*
  • Time Factors
  • Treatment Outcome
  • Wakefulness / drug effects

Substances

  • Melatonin